Stockwinners Market Radar for June 01, 2023 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

20:18 EDT Cathie Wood's ARK Investment sold 325K shares of Nu Holdings today

19:06 EDT RMG Acquisition Corp. III receives Nasdaq listing delinquency letter - RMG Acquisition Corp. III announced that it received a delinquency notification letter from the Listing Qualifications Staff of the Nasdaq Stock Market LLC on May 25, 2023 due to the company's non-compliance with Nasdaq Listing Rule 5250(c)(1) as a result of the company's failure to timely file its Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2023. The Listing Rule requires listed companies to timely file all required periodic financial reports with the Securities and Exchange Commission. The company filed the Form 10-Q with the SEC on June 1, 2023. On June 1, 2023, the company received a letter from Nasdaq indicating that based on the company's June 1, 2023 filing of the Form 10-Q, the Staff has determined that the company has complied with the Listing Rule and, accordingly, the matter was closed. As a result, the company is currently in compliance with the Nasdaq Listing Rules and the company's securities will continue to trade on The Nasdaq Capital Market.

18:36 EDT Rio Tinto to invest $395M in Pilbara desalination plant - Rio Tinto plans to invest $395M in a seawater desalination plant in the Pilbara, Western Australia, to support future water supply for the company's coastal operations and communities in the region. The proposed Dampier Seawater Desalination Plant, which remains subject to Commonwealth and State Government approvals, will be located within Rio Tinto's existing iron ore port operations at Parker Point. It will have an initial nominal capacity of four gigalitres annually with the potential for this to increase to eight gigalitres in the future. The project includes construction of a new supply pipeline to connect to the existing water network. Subject to relevant approvals, construction is expected to commence in 2024 with the facility expected to be operational and producing water in 2026. At the peak of construction, the project is expected to support approximately 300 jobs. Rio Tinto have been engaging with all associated Traditional Owners and Custodians in relation to the project and would like to thank the Ngarluma people, on whose Traditional lands the plant will be constructed, and Murujuga Aboriginal Corporation, who represent the five Traditional Owner groups in the region.

18:23 EDT Crowdstrike CEO: Excited to reach GAAP profitability so quickly - In an interview on CNBC's Money, George Kurtz said it's still a challenging environment with deals taking longer. Crowdstrike has been focused on generative AI for some time. AI is the foundational element of why the company was started, he noted. Legacy tech is not capable of stopping security breaches and that is why they turn to companies like Crowdstrike, he added.

17:58 EDT McKesson GC sells $4.18M in common stock - In a regulatory filing, McKesson disclosed that its General Counsel Lori Schechter sold 11.2K shares of common stock on May 31st in a total transaction size of $4.18M.

17:53 EDT Crispr Therapeutics CEO Kulkarni sells $1.6M in company shares - The CEO of Crispr Therapeutics Samarth Kulkarni disclosed in a regulatory filing that he had sold 25,000 shares of company stock at $64.88 per share on May 30, for a total transaction amount of $1,621,893.

17:34 EDT Brown & Brown names Barry Hensley CSO, Rob Burch as CISO - Brown & Brown (BRO) has announced the appointment of Barry Hensley as chief security officer, or CSO, and Rob Burch as chief information security officer, or CISO, for Brown & Brown. Before joining Brown & Brown, Hensley served as the chief threat intel officer and senior vice president for Secureworks (SCWX). Prior to joining the Company, Burch held the role of senior vice president and chief information security officer for Fidelity National Financial.

17:29 EDT Raytheon Technologies awarded $621.4M Missile Defense Agency contract - Raytheon was awarded an indefinite-delivery/indefinite-quantity contract with a maximum amount of $621.4M. Under this new contract, the contractor will maintain the equipment, facilities, and personnel required to transport, test, upgrade, and repair existing Exo-atmospheric Kill Vehicles in a variety of configurations. A delivery order in the amount of $84.3M is being issued. The work will be performed in Tucson, Arizona. The ordering period is from June 1 through May 31, 2028. One offer was solicited and one offer was received. FY23 research, development, test and evaluation funds in the amount of $16.31M are being obligated on this award. The Missile Defense Agency is the contracting activity.

17:08 EDT Dell 'encouraged' over potential for future S&P 500 inclusion - On its quarterly call, Dell Technologies said that, with recent S&P Global eligibility rule changes, it is "encouraged" about the potential for future inclusion in the S&P 500 Index.

17:02 EDT Shawcor sells Shaw Pipeline Services business to U.S.-based investor group - Shawcor announced that it has sold its Shaw Pipeline Services operating unit to a US-based investor group which includes Achieve Capital LLC and members of current SPS management. This transaction resulted from the company's previously announced strategic review process. With this sale, the company's Pipeline and Pipe Services segment will consist entirely of the Pipeline Performance Group operating unit, for which a previously communicated strategic review process is ongoing. "Today's announcement is consistent with the Company's strategy to direct capital into a more focused portfolio, driving organic and inorganic growth within its high value, materials technology based Composite Systems and Automotive and Industrial segments, lowering volatility while driving higher margins, free cash flow, and returns for shareholders," said Mike Reeves, Shawcor's President and CEO. "We deeply appreciate the many contributions of those employees who work within SPS and firmly believe this pending transaction will position them for future success."

16:54 EDT AlTi Global CFO Christine Zhao stepping down - AlTi Global announced that Christine Zhao will be stepping down as CFO effective June 15. Reid Parmelee, AlTi's Global Controller, has been appointed interim CFO. Parmelee will continue in his current capacity as Global Controller. Zhao will remain with the Company in the coming weeks. The company has engaged a global executive search firm and commenced its search for a successor. Reid Parmelee has served as Global Controller for AlTi since October 2021. Before joining AlTi, Parmelee served as a Controller for Prospect Capital, a publicly-traded Business Development Company. He started his career at PwC as an auditor and then joined the Transaction Services practice.

16:48 EDT FlexShopper regains compliance with Nasdaq - FlexShopper announced that the company has regained compliance with the Nasdaq's Minimum Bid Price Requirement.

16:46 EDT Elastic falls 7.2% to $66.50 after Q4 results and guidance

16:42 EDT SentinelOne down 32% at $14.01 per share after Q1 results, guidance cut

16:40 EDT Lululemon reports Q1 SSS up 13% - Lululemon Q1 comparable store sales increased 13%, or 16% on a constant dollar basis. Direct to consumer net revenue increased 16%, or 18% on a constant dollar basis. Direct to consumer net revenue represented 42% of total net revenue compared to 45% for the first quarter of 2022.

16:36 EDT Connect Biopharma announces data from Phase 2 trial of icanbelimod to treat UC - Connect Biopharma Holdings Limited announced positive data at Week 48 from Phase 2 trial CN002 for icanbelimod, a once-daily, orally administered, selective sphingosine 1-phosphate receptor 1 modulator in development for the treatment of ulcerative colitis UC ..."Current treatment options for UC have not demonstrated break-through efficacy based on clinical remission, highlighting the need for new and more effective therapies. Based on the icanbelimod 0.2 mg data, the clinical remission efficacy, safety data and absolute lymphocyte count reduction are compelling," said Brian Feagan, M.D., Professor in the Departments of Medicine, Epidemiology and Biostatistics at the Shulich School of Medicine & Dentistry, University of Western Ontario. "Additionally, because icanbelimod has rapid recovery of lymphocytes upon discontinuation and high potency, there is an opportunity to optimize the dosing strategy in future trials to further enhance the already encouraging efficacy data," added Dr. Feagan."These promising data from the maintenance period of CN002 further support the potential of icanbelimod to be not only a best-in-class S1P1 modulator, but also an important new treatment option among current standard of care therapies, offering patients with UC a much-needed sustainable control of inflammation," said Zheng Wei, Ph.D., Co-Founder and CEO of Connect Biopharma. "We are actively exploring strategic partnerships to advance icanbelimod into a registrational program to realize its therapeutic potential. In addition, we plan to submit the full data from the study to a medical congress later this year."

16:34 EDT Stratasys receives unsolicited takeover proposal from 3D Systems - Stratasys Ltd. (SSYS) announced that it has received an unsolicited non-binding indicative proposal from 3D Systems Corporation (DDD) to acquire Stratasys for $7.50 in cash and 1.2507 newly issued shares of common stock of 3D Systems per ordinary share of Stratasys. As announced on May 25, 2023, Stratasys entered into a merger agreement with Desktop Metal, Inc. (DM) under which Stratasys and Desktop Metal will combine in an all-stock transaction. The transaction, which is expected to be completed in the fourth quarter of 2023, is subject to customary closing conditions, including the approval of Stratasys' shareholders and Desktop Metal's stockholders and the receipt of certain governmental and regulatory approvals. The Stratasys Board of Directors will carefully review the 3D Systems proposal, in accordance with its fiduciary duties, and its obligations under Stratasys' merger agreement with Desktop Metal, in consultation with its independent financial and legal advisors. The Stratasys Board has not made any determination as to the 3D Systems proposal within the framework contemplated by the Desktop Metal merger agreement, which remains in effect, nor changed its unanimous approval, recommendation and declaration of advisability of the agreed transaction with Desktop Metal. Stratasys shareholders do not need to take any action at this time with respect to the 3D Systems proposal.

16:32 EDT Darling Ingredients signs LOI with Butterball on potential new poultry plant - Darling Ingredients announced it has entered into a letter of intent with Butterball to explore the construction of a new poultry rendering plant adjacent to Butterball's Mt. Olive, North Carolina, facility. The new facility being explored is anticipated to be able to process about 18M pounds of material weekly through three lines. Pending permits and the execution of definitive agreements, construction would likely begin in early 2024 and be completed in 2025.

16:31 EDT Medtronic names Ken Washington new Chief Technology and Innovation Officer - Medtronic has named Ken Washington Medtronic Chief Technology and Innovation Officer. Washington will also become a member of the Medtronic Executive Committee. Washington joins Medtronic from Amazon where he served as Vice President and General Manager of Consumer Robotics. Prior to that, he was Chief Technology Officer at Ford Motor Company; and he spent seven years at Lockheed Martin in various leadership roles including Chief Technology Officer, Chief Privacy Officer and Vice President, Advanced Technology Center, Lockheed Martin Space Systems Company.

16:29 EDT Service Properties acquires Nautilus Hotel in South Beach Miami - Service Properties Trust "announced that it has acquired the 250-room Nautilus Hotel located at 1825 Collins Avenue, Miami Beach, FL for $165.4 million, or approximately $661,600 per key. The Nautilus is a lifestyle oceanfront hotel located in Miami's South Beach neighborhood with 250 guestrooms, including 55 suites, four food and beverage outlets, outdoor pool, spa, fitness center and 17,500 SF of flexible outdoor and indoor event space. The hotel will initially be branded as the Nautilus Sonesta Miami Beach, and undergo a $25 million repositioning commencing in the Summer of 2024 with plans to reopen in early 2025 under Sonesta's lifestyle brand, The James."

16:28 EDT Darling Ingredients enters into LOI with Butterball over new poultry plant - Darling Ingredients announced it has entered into a letter of intent with Butterball, LLC to explore the construction of a new poultry rendering plant adjacent to Butterball's Mt. Olive, North Carolina, facility. The new facility being explored is anticipated to be able to process about 18 million pounds of material weekly through three lines. Pending permits and the execution of definitive agreements, construction would likely begin in early 2024 and be completed in 2025. "Darling Ingredients is committed to supporting its customers and agricultural growth in North Carolina," said Randall C. Stuewe, Darling Ingredients Chairman and Chief Executive Officer. "A new Mt. Olive rendering facility strengthens rendering reliability, increases capacity and provides a critical service that transforms this material into invaluable ingredients and feedstock for renewable diesel and sustainable aviation fuel."

16:25 EDT Ready Capital announces $100M share repurchase program - Ready Capital announced that its board of directors approved a stock repurchase program authorizing the repurchase of up to $100M of the company's common stock. Repurchases under the stock repurchase program may be made at management's discretion from time to time on the open market, in privately negotiated transactions or otherwise, in each case subject to compliance with all Securities and Exchange Commission rules and other legal requirements, and may be made in part under one or more Rule 10b5-1 and Rule 10b-18 plans, which permit stock repurchases at times when the company might otherwise be precluded from doing so. The timing and amount of any repurchase transactions will be determined by the company's management based on its evaluation of market conditions, share price, legal requirements and other factors.

16:25 EDT Bridge Investment unit acquires manufacturing assets in Pennsylvania - Bridge Net Lease announced that it has acquired two off-market manufacturing and distribution assets located in Hazleton, PA, totaling 283,450 square feet. The assets, located at the intersection of two critical interstate highways, are 100% leased on 15-year absolute net leases with two additional 5-year options. The mission critical assets serve as the tenant's sole US manufacturing and distribution facilities. The transaction was brokered by the CBRE National Partners Northeast team consisting of Mike Hines, Brian Fiumara, Brad Ruppel, Joe Hill, and Lauren Dawicki, along with Vincent Ranalli and Tony Gruenling.

16:22 EDT Momentus to partner with Axient on space activities - Momentus, a U.S. commercial space company that offers orbital transportation and in-space infrastructure services, and Axient LLC have entered into a Memorandum of Understanding to collaborate on technologies and capabilities to serve customers from Low-Earth Orbit to Cislunar space. The two companies will work together to propose and develop capabilities to address a wide variety of space activities such as, but not limited to, launch services, space communication, space domain awareness, precision navigation and timing, and related technologies to utilize in, from, or through the Low-Earth Orbit, Geostationary Transfer Orbit, Geostationary Orbit, and Cislunar domains.

16:21 EDT Heritage Global announces new upsized $17M credit facility - Heritage Global "announced an upsized $17 million credit facility with C3bank which includes the renewal of its existing $10 million line of credit as well as a new $7 million term loan. Ross Dove, CEO of Heritage Global, commented: "We are seeing strong growth across our business and this new credit agreement with C3bank increases our borrowing capacity and further supports our ability to continue to go after the opportunities we are seeing in the marketplace. C3bank has been an excellent lender for us, and we appreciate their partnership as we execute on our strategy and drive value for our shareholders."

16:20 EDT Wheels Up approves 1-for-10 reverse stock split - Wheels Up approved a reverse stock split of Class A common stock, par value $0.0001 per share, at a ratio of 1-for-10. The Reverse Stock Split is expected to become effective immediately after the close of trading on the "NYSE on June 7 and Wheels Up's Common Stock will begin trading on the NYSE on a reverse split-adjusted basis on June 8 under the ticker symbol "UP". Following the Reverse Stock Split, the Company's Common Stock will have a new CUSIP number - 96328L205 - and ISIN number - US96328L2051 -. Wheels Up's publicly-traded warrants will continue to be traded on the NYSE under the symbol "UP WS" and the CUSIP and ISIN numbers for the publicly-traded warrants will not change. The total number of shares of Common Stock authorized for issuance under the company's Certificate of Incorporation will be reduced by a corresponding ratio from 2.5B shares to 250M shares. The company does not plan to issue fractional shares in connection with the Reverse Stock Split.

16:18 EDT MongoDB jumps 18% to $346.49 after Q1 results, FY24 guidance beat estimates

16:07 EDT Five Below sees Q2 comparable sales up 2%-3%

16:06 EDT Trinity Capital provides $30M in growth capital to Revelle Aesthetics - Trinity Capital announced the commitment of $30M in growth capital to support Revelle's efforts in developing aesthetic solutions that deliver meaningful results for women and reliable outcomes for practitioners. Through this investment, Revelle aims to bolster the growth and expansion of its operations, enabling them to further penetrate the market. The infusion of capital will aid in driving sales and support marketing initiatives to reach a wider customer base and expand production capabilities.

16:02 EDT Alkermes names Caroline Loew, Ph.D as CEO designate of Mural Oncology - Alkermes announced that Caroline Loew, Ph.D., has been appointed as the CEO designate of Mural Oncology, the new independent public company to be established upon the planned separation of Alkermes' oncology business. Dr. Loew will join Alkermes in June as a strategic advisor and transition to CEO of Mural Oncology upon completion of the separation. The planned separation remains on track for completion in 2H23.

16:01 EDT Radiant Logistics expands Service By Air Network to Boston, MA - Radiant Logistics announced the continued expansion of its Service By Air Network with a new location in Boston, Massachusetts. The Boston operation will leverage Radiant's robust technology platform, purchasing power and global network to provide a comprehensive level of domestic and international freight forwarding and logistics services.

15:46 EDT BofA CEO says 'engineered' headcount down, not making layoffs - Asked about BofA's headcount at Bernstein's Strategic Decisions Conference, BofA CEO Brian Moynihan said: "So we - at the end of the day, our company has in its $60-odd billion expenses, $36 billion in comp. And then of the other $20-odd billion - $25 billion or so, it is basically a lot for the buildings and a lot of the computers that the team works on. And so it's all about the people count... When I talk about reductions in heads, it's not layoffs, it's actually moving people in the company around and we have a very - Sheri Bronstein and team run a very disciplined process to redeploy. So we - Alistair said at the earnings call, we'd be at [213] at the end of the quarter and we're there and that looks like it's well in hand. Now in a broader economic sense, just to give you a sense, May last year, we hired 3,000 people. May this year, we'll hire 600 or 700. Think about that in the market in terms of us and all these other employers doing it. That's the softness in the labor market... And so we were targeting to reduce the heads in these areas we didn't redeploy. So if we'll hire 600, 700, we'll have like 1,300, 1,400 leave the company, part attrition, part for retirements, part for leaves of absence whatever reasons and your headcount comes down. So we've engineered that down."

15:31 EDT Bank of America CEO sees sales trading business 'about flattish' this quarter - Asked about BofA's capital markets business at Bernstein's Strategic Decisions Conference, BofA CEO Brian Moynihan said: "So there's a lot of activity. Your question with the result in deals and stuff. And there's people lining up equity raises and there's people lining up other stuff, it's just -- you just got to get, I think, a notion that the tightening pretty stopped or the incremental from here to there will be small enough that people can sort of adjust it, and I think it will come through. But we actually gained share as the world came down. We kept more flat. And on the sales trading side, frankly, I think we'll be flattish this quarter, which it may be very strong performance. Jimmy DeMare and the team have done a great job of sort of stabilizing that business and keeping it a little less up and down than some of our comparisons. And that then holds us in good stead. So -- whether we end up exactly flat or not, I think it's kind of -- right now, it's down a little bit, but the next month is typically a little stronger month for us. And so think about flattish, and that's pretty good."

15:17 EDT Dell Technologies up 5% after early release of Q1 results - Shares of Dell Technologies are up $2.22, or 5%, to $47.03 following the company's release of its Q1 report before the closing bell.

15:07 EDT Dell Technologies reports Q1 cash flow from operations $1.8B

15:03 EDT Dell Technologies says 'executed well against a challenging economic backdrop' - "We executed well against a challenging economic backdrop," said Chuck Whitten, co-COO, Dell Technologies. "We maintained pricing discipline, reduced operating expenses, and our supply chain continued to perform well after normalizing ahead of competitors. We announced a record number of innovations, making good on our promise to extend Dell APEX as-a-Service capabilities across our full portfolio and simplifying multicloud and edge computing for our customers." "We continue to create value for stakeholders, with strong first quarter cash flow from operations of $1.8 billion," said Tom Sweet, CFO, Dell Technologies. "We've returned $5 billion to shareholders over the last six quarters, well ahead of our free cash flow return target, and we continue to invest in innovation that will fuel our growth."

15:01 EDT Bank of America CEO says loan growth to be 'flattish' this quarter - While asked about loan growth at Bernstein's Strategic Decisions Conference, BofA CEO Brian Moynihan said: "I think we're seeing consumers sort of flattish largely that's because mortgages are sort of dead a little better than the card, everything else is sort of floating around. On the commercial, like the line usage dropped about 1,000 basis points in pandemic, got back about half of that. And then I thought -- everybody thought well, they will just go back up, that's like, say, it's 42% to 32%. Everybody thought it would just sort of march up there. It sort of flattened out in the 36% range sort of in the aggregate to give you a sense. And that means going back to the inflation rate, that means companies are not seeing the need to draw on our lines and it's more expensive, they will be much more careful... So loan growth will be flattish this quarter. And that's probably a little bit less than we expected, but generally in line."

14:45 EDT Dell Technologies trading halted, news pending

14:34 EDT Tigo Energy Inc trading halted, volatility trading pause

14:05 EDT Illumina announces AI algorithm that predicts disease-causing genetic mutations - Illumina announced the new PrimateAI-3D, an artificial intelligence algorithm that it says predicts disease-causing genetic mutations in patients. The results are published in two papers in the June 2 issue of Science. The company said: "PrimateAI-3D utilizes deep neural network architectures similar to ChatGPT and AlphaFold, but is trained on genome sequences rather than human language. However, unlike generative language models such as ChatGPT, where existing texts can be used to inform training, the genetic variants that cause disease in the human genome are largely unknown. To overcome this, PrimateAI-3D effectively uses natural selection to train the parameters of the deep neural network, using millions of benign genetic variants identified through the sequencing of 233 diverse primate species, the largest such sequencing effort of nonhuman primate species to date. Sequencing nonhuman primates can help scientists infer the pathogenicity of human genetic variants, and thus improve clinical variant interpretation on a genome-wide scale. The result is a deep neural network that has been shown to identify disease-causing variants with superior accuracy in all six clinical cohorts that were tested, and provide individualized predictions of genetic disease risk that have been validated in a cohort of nearly half a million people."

13:41 EDT Jupiter Wellness Acquisition Corp trading resumes

13:19 EDT JANA files lawsuit to stop Freshpet board's actions to 'manipulate' vote - JANA Partners, which along with its affiliates and partners owns 9.5% of Freshpet, has filed a complaint in the Court of Chancery of the State of Delaware against Freshpet and the company's Board of Directors. The complaint seeks a declaratory judgment and a determination that the Board's recent actions to entrench itself, and refusal to reverse them, constitute breaches of fiduciary duties; and an order requiring that the number of directors up for election at the company's 2023 Annual Meeting of Stockholders be returned to its original size, such that four director seats, rather than three, stand for election at the Meeting. "JANA filed the complaint in response to the highly entrenching actions Freshpet took on May 17, 2023, which included changing the size and composition of its Board such that the number of directors up for election at the Meeting was reduced from four to three, and unexpectedly accelerating the date of the Meeting-in the midst of settlement discussions with JANA regarding Board composition, conflicts and governance issues-from its usual mid-Fall meeting date to July 25, 2023. JANA's filing contends that the Board's extraordinary actions, taken well after JANA publicly disclosed its interest in obtaining representation on Freshpet's Board, constitute a breach of the Board's fiduciary duties, and that JANA should have the opportunity to nominate four Class III directors at the Meeting. JANA has also filed a motion to expedite these proceedings to resolve this critical issue ahead of the recently-advanced deadline to nominate directors for consideration at the Meeting. The Board's decision to accelerate the date of the 2023 Annual Meeting, announced on May 17, 2023, required that stockholders submit any director nominations within just nine days of the announcement, a clear entrenchment tactic by the Board to avoid accountability to Freshpet's shareholders."

12:46 EDT CFPB finds billions of dollars stored on payment apps lack may federal insurance - The Consumer Financial Protection Bureau published an issue spotlight on digital payment apps heavily used by consumers and businesses. The analysis finds that funds stored on these apps may not be safe in the event of financial distress, since the funds may not be held in accounts with federal deposit insurance coverage. The CFPB also issued a consumer advisory for customers holding funds in these apps and how they can make sure their funds remain safe. "Popular digital payment apps are increasingly used as substitutes for a traditional bank or credit union account but lack the same protections to ensure that funds are safe," said CFPB Director Rohit Chopra. "As tech companies expand into banking and payments, the CFPB is sharpening its focus on those that sidestep the safeguards that local banks and credit unions have long adhered to." Use of nonbank payment apps such as PayPal (PYPL), Venmo, and Cash App (SQ) have rapidly grown in the past few years. These apps allow people to quickly pay retailers and others, while providing the option to store funds. Unlike traditional bank and credit union accounts which have deposit insurance, funds stored in these nonbank payment companies may be unprotected. The agency also issued a notice to consumers advising them to transfer balances to insured banks and credit unions. Reference Link

12:44 EDT Interactive Brokers reports May DARTs down 19% y/y - Interactive Brokers Group reported its Electronic Brokerage monthly performance metrics for May. Brokerage highlights for the month included: 1.860 million Daily Average Revenue Trades, 19% lower than prior year and 5% higher than prior month. Ending client equity of $345.1 billion, 10% higher than prior year and 1% higher than prior month. Ending client margin loan balances of $39.8B, 10% lower than prior year and 1% higher than prior month. Ending client credit balances of $98.7B, including $2.9B in insured bank deposit sweeps, 8% higher than prior year and 1% lower than prior month. 2.26 million client accounts, 19% higher than prior year and 2% higher than prior month. 186 annualized average cleared DARTs per client account. Average commission per cleared Commissionable Order of $3.08 including exchange, clearing and regulatory fees.

12:19 EDT Fisker to begin volume deliveries of Fisker Ocean in U.S. week of June 19 - Fisker will commence volume deliveries to US customers the week of June 19. As of May 31, the all-electric Fisker Ocean Extreme has an Environmental Protection Agency estimated total range of 360 mile on standard 20-inch wheels and tires.

12:00 EDT C3.ai falls -10.2% - C3.ai is down -10.2%, or -$4.09 to $35.92.

12:00 EDT MDU Resources falls -31.7% - MDU Resources is down -31.7%, or -$9.26 to $19.93.

12:00 EDT Biohaven rises 20.8% - Biohaven is up 20.8%, or $3.65 to $21.16.

11:42 EDT Conn's says May same-store sales down about 17% - On the Conn's Q1 earnings call, the company stated that overall sales trends have "improved or remained stable since last year's third quarter." The company added, according to a transcript of the call: "Positive momentum in both Conn's in-house finance sales and LTO sales has continued in May, but has been offset by weaker trends to cash and higher credit quality customers. As a result, total retail sales for the month of May were down approximately 14%, while same-store sales were down approximately 17%. We believe we are well-positioned to offset the softness from cash and higher credit quality consumers later this year as we benefit from our strategic initiatives, including the recent launch of our in-house lease-to-own product known as Improvement Financial. Like other transformations the company has been through over the last 20 years, bringing the LTO business in-house has the potential to contribute to significant growth in both revenue and earnings in the coming years."

11:32 EDT Par Pacific completes acquisition of Exxon Mobil Billings refinery - Par Pacific Holdings (PARR) has closed its previously announced acquisition of the Billings refinery and associated marketing and logistics assets from ExxonMobil Corporation (XOM) and two of its subsidiaries. The base purchase price of $310M, including $30M Par Pacific funded at signing, was paid with cash on hand, and hydrocarbon inventory associated with the Billings Acquisition was primarily financed by the company's ABL credit facility. Going forward, the refinery and logistics business will be known as Par Montana.

11:05 EDT New Jersey American Water completes acquisition of Egg Harbor City systems - New Jersey American Water has completed its acquisition of the water and wastewater systems of Egg Harbor City, N.J. for $21.8M. The sale of these systems, which serve approximately 3,000 customer connections combined, follows the approval of the New Jersey Department of Community Affairs and the New Jersey Board of Public Utilities, and is the first in the state of New Jersey to be completed through the Water Infrastructure Protection Act/

10:38 EDT Goldman 'tracking down a little over 25%' y/y in FICC, Equities, says Waldron - Comments taken from the Bernstein Strategic Decisions conference.

10:23 EDT Lockheed Martin sees F-35 reaching annual output of 156 within two years - Says on track to build F-16 at a 3 jet/month rate by 2024.

10:18 EDT Bayer in exclusive license pact to develop and commercialize Cedilla inhibitors - Bayer and Cedilla Therapeutics announced an exclusive license agreement to develop and commercialize Cedilla Therapeutics' CyclinE1/CDK2 complex inhibitors which selectively address oncogenic drivers. Under the terms of the agreement, Bayer will receive full rights on the development and commercialization of Cedilla's CyclinE1/CDK2 complex inhibitors. Cedilla will receive an upfront payment and potential development and commercial-based milestone payments. Cedilla will also be eligible to receive royalties on medicines based on their technology commercialized by Bayer. Financial details have not been disclosed. Dominik Ruettinger, M.D., Ph.D., Global Head of Research and Early Development for Oncology, Pharmaceuticals Division, Bayer AG, said: "We look forward to progressing Cedilla's programs and continuing to focus on assets that allow better patient selection. With our oncology strategy, we are dedicated to accelerating the research and development of novel cancer therapies that have the potential to make a meaningful difference in the lives of patients."

10:16 EDT Dollar General has seen positive comp sales through first 3 weeks of Q2 - Comments taken from Q1 earnings conference call.

10:10 EDT Walgreens, Vitamin Angels expand prenatal pilot program to nearly 400 stores - Vitamin Angels and Walgreens have announced the expansion of their prenatal pilot program to nearly 400 Walgreens stores nationwide, including a direct ship option in certain markets. The program provides free prenatal vitamins and nutrition education materials to pregnant people in underserved communities through participating Walgreens pharmacies. The prenatal vitamin pilot program originally launched in 2021 in select Walgreens stores across the South Side and West Side of Chicago and has reached over 1,200 pregnant people to date. The expansion will bring the program to 12 additional markets across the U.S., and will further test distribution methods to determine the most effective ways to reduce barriers to accessing prenatal vitamins for pregnant people in need.

10:03 EDT PowerSchool expands partnership with Maryvit Education Center - PowerSchool announced Maryvit Education Center in Chonburi, Thailand has expanded its use of PowerSchool Schoology Learning, a key component of the PowerSchool Personalized Learning Cloud, to support K-10 students at its new campus, which opened in May 2023. With MEC's newest campus open for the 2023-24 school year, MEC teachers will have access to intuitive tools to improve student performance, collaboration, parental and family engagement, and standards tracking.

10:00 EDT Dollar General falls -16.3% - Dollar General is down -16.3%, or -$32.84 to $168.25.

10:00 EDT MDU Resources falls -31.1% - MDU Resources is down -31.1%, or -$9.07 to $20.11.

10:00 EDT Pure Storage rises 15.4% - Pure Storage is up 15.4%, or $4.44 to $33.23.

09:53 EDT Panbela Therapeutics Inc trading resumes

09:47 EDT C3.ai falls -20.8% - C3.ai is down -20.8%, or -$8.31 to $31.70.

09:47 EDT Pure Storage rises 12.7% - Pure Storage is up 12.7%, or $3.65 to $32.44.

09:47 EDT Chewy rises 22.2% - Chewy is up 22.2%, or $6.54 to $36.03.

09:43 EDT Carvana trading resumes

09:38 EDT nCino trading resumes

09:37 EDT SunCar Technology Group Inc trading resumes

09:32 EDT SunCar Technology Group Inc trading halted, volatility trading pause

09:24 EDT Arcturus Therapeutics granted fast track designation from FDA for ARCT-810 - Arcturus Therapeutics announced that the FDA has granted fast track designation to ARCT-810, the company's mRNA therapeutic candidate for ornithine transcarbamylase deficiency.

09:20 EDT Celularity announces publication of preclinical data in Cytotherapy - Celularity announced the online publication of preclinical data in Cytotherapy, the official journal of the International Society of Cell and Gene Therapy, ISCT. The paper, "Characterization of CRISPR/Cas9-edited human placental allogenic stromal cells with low tissue factor expression and reduced thrombotic effects," examined methods to reduce the tissue factor expressed by allogeneic stromal cells, which has been regarded as a safety concern in clinical applications as it may trigger thrombosis when ASCs are administered intravenously. Using CRISPR gene editing of ASCs, the study demonstrated that efficient TFKO can be achieved, generating ASCs with significantly reduced TF activity without affecting the critical features and functions of the cells. The authors concluded that the TF gene knockout provides a feasible strategy which may improve the clinical safety features of ASC-based cell therapies. "We are very encouraged by these results with an edited version of one of our cell therapy candidates," said Robert J. Hariri, M.D., Ph.D., Celularity's CEO, Chairman and Founder. "These data advance our understanding of the potential for ASCs to safely address human diseases. These data also are guiding our investment decision to progress our novel genetically modified allogeneic placental-derived mesenchymal-like adherent stromal cells (MLASCs), APPL-001, in diseases like Crohn's disease, facioscapulohumeral muscular dystrophy, and to explore a range of other clinical indications."

09:19 EDT Biofrontera begins development of portable PDT lamp for use with Ameluz-PDT - Biofrontera engaged a contract manufacturer to develop a new, low-cost portable photodynamic therapy lamp for use with Ameluz. Prior to this engagement, Biofrontera acquired one issued U.S. patent and all rights from one of two inventors on another issued U.S. patent related to a portable red-light lamp for use in PDT. The inventors of the patents are working with Biofrontera on the lamp development. Biofrontera will make regulatory and commercial milestone payments to the patent holders, and will also pay royalties on future net sales of products utilizing the acquired patents.Development of a prototype portable PDT lamp is expected to begin later this month.

09:17 EDT TG Therapeutics announces EC granted approval of BRIUMVI for treatment of RMS - TG Therapeutics announced that the European Commission, EC, has granted approval of BRIUMVI for the treatment of adult patients with relapsing forms of multiple sclerosis, RMS, with active disease defined by clinical or imaging features. BRIUMVI was granted approval by the U.S. Food and Drug Administration on December 28, 2022, for the treatment of RMS in adults. BRIUMVI is the first and only anti-CD20 monoclonal antibody approved in the U.S. and now the European Union, EU, for adult patients with RMS that can be administered in a one-hour infusion following the starting dose. Michael Weiss, the Company's Chairman and Chief Executive Officer, stated, "We are very pleased that the European Commission has approved BRIUMVI for the treatment of adult patients with multiple sclerosis. This brings us one step closer to our goal of providing MS patients in Europe with an alternative treatment option that can be delivered in a one-hour infusion every 6 months following the starting dose and we are targeting commercial availability later this year."

09:16 EDT TaskUs launches TaskGPT, powered by Generative AI - TaskUs (TASK) announced the launch of TaskGPT, a powerful customer service application powered by Generative AI. The new offering builds on TaskUs' work with the generative AI companies creating powerful tools for its global business of 47,700 employees. "We are excited about the revolution taking place in Generative AI and our ability to take advantage of massive technological benefits to increase the efficiency of TaskUs and our clients," said Bryce Maddock, Co-Founder and CEO of TaskUs. "We are thrilled to build on the knowledge we've accumulated internally and deliver solutions for clients. We believe so strongly in the transformative abilities of our AI-based tools and knowledge that we've developed a new revenue model for the business that will see us compensated based on the outcomes we deliver." TaskUs announces MoneyLion (ML), a leading financial technology company, as an inaugural partner that is utilizing TaskGPT.

09:15 EDT Atossa Therapeutics appoints Weaver as CFO - Atossa Therapeutics announces the appointment of Greg Weaver as the Company's new Chief Financial Officer, CFO. Weaver succeeds Kyle Guse. Weaver brings more than 30 years of life sciences, financial and operations experience to the Company. Recently, he served as CFO of privately held BioIntelliSense, a commercial stage med-tech company focused on remote patient monitoring.

09:11 EDT Great Lakes Dredge announces receipt of $186.6M in awarded work - Great Lakes Dredge & Dock Corporation announced the receipt of two major dredging awards totaling $186.6M. The awarded work includes: Freeport Harbor Channel Improvement Project, Dredging Reaches 1, 2, and 4; Galveston Entrance Channel and Houston Ship Channel Dredging Project. Lasse Petterson, President and Chief Executive Officer commented, "Great Lakes is pleased to add the above work to our backlog of capital and maintenance dredging projects. The Freeport Channel Improvement Project is one of the first capital projects to be awarded by the U.S. Army Corps of Engineers in 2023 and we anticipate several more capital projects to enter the market before the end of the year. We are proud to bring our strong safety culture and experience as the contractor on both of these projects. There is a great need for the above listed projects and similar projects to continue to support the overall improvement and resiliency of our country's environment, coastlines and infrastructure."

09:10 EDT Vera Bradley, Sanrio debut co-branded Hello Kitty collection - Vera Bradley announced that Vera Bradley has collaborated for the first time with global lifestyle brand Sanrio, best known for internationally recognized pop icon Hello Kitty, to unveil a co-branded collection. The Vera Bradley Hello Kitty collection is now available to shop in Vera Bradley stores nationwide and online. "Like Vera Bradley, Sanrio has a rich heritage rooted in the gift industry, appeals to a multi-generational customer base, and is passionate about spreading joy and inspiring optimism through its products," noted Jackie Ardrey, CEO of Vera Bradley. "Our customers have been asking for this collaboration over the years, so we are delighted to partner with Sanrio to finally bring the Vera Bradley Hello Kitty collection to life."

09:07 EDT Parsons integrates artificial intelligence across operations - The company said, "Parsons Corporation has seamlessly integrated artificial intelligence across its operations, markets and solutions, and corporate functions to enhance efficiency, accuracy, decision-making, and accelerate customer solutions. This embedded AI approach empowers Parsons to deliver innovative business solutions by automating complex processes, analyzing critical data, and enabling predictive modeling for project management, technology and product development, workforce planning, business capture enhancement, and resource allocation; ensuring that the company is delivering AI-empowered solutions from the lab to the mission at scale. The company strategically uses AI across its Federal Solutions and Critical Infrastructure segments to revolutionize operational capabilities and drive impactful outcomes. AI is used throughout Federal Solutions to evaluate massive amounts of data, enable real-time decision-making, and enhance all-domain situational awareness, threat detection, and response effectiveness - with the goal of accelerating mission success for the warfighter. Innovations in the company's national security business include a computer vision object detection framework that detects and classifies small Unmanned Air Systems in real-time; systems that autonomously create representative cyber infrastructures for a known adversary based on collected information; and autonomous electronic warfare planning tools that optimize the placement and configuration of EW devices based on the RF battlespace. Parsons also recently won a classified research and development contract to develop constellation task scheduling algorithms based on organically developed AI technology. In the company's Infrastructure segment, AI is deployed to improve project planning and execution, enabling predictive maintenance, advancing asset management, and facilitating the efficient allocation of resources for critical infrastructure projects. Parsons internally developed a tool to evaluate the urban form of existing and future developments, using machine learning to predict a project's walkability, the effect of proximity to public transit, land use mix, and land use density. The model is used in several of the company's large design infrastructure efforts around the world to improve sustainability, safety, and economic access."

09:06 EDT Philips, Masimo announces extension of collaboration - Royal Philips (PHG) and Masimo (MASI) announced FDA clearance allowing the activation of SedLine Brain Function Monitoring, Regional Oximetry, and CO2 measurements in Philips Patient Monitors - IntelliVue MX750 and MX850. The latest extension of Masimo and Philips' ongoing collaboration will help enable clinicians to make quick and informed decisions without the need for additional monitoring equipment. "Combining our expertise in noninvasive monitoring and signal processing technologies with Philips' expertise in integrated patient monitoring and therapy solutions is a win-win for patients and clinicians alike," said Jon Coleman, President of Worldwide OEM Sales and Global Health, Masimo. "We are proud that Philips has chosen to make our innovative SedLine, O3, and NomoLine technologies available to their customers. We look forward to continuing our partnership with a focus on improving patient outcomes and reducing the cost of care."

09:03 EDT HUMBL, Swish Foundation enter basketball marketing partnership - HUMBL announced a marketing partnership with the Swish Foundation 501(c)3 and the Swish Pro-Am Summer League. As part of the marketing sponsorship, the HUMBL logo will be displayed on both the jerseys and the court at each Swish Pro-Am game. Select Swish Pro-Am merchandise will also be Verified by BLOCKS and commemorated on the BLOCKS Registry to improve the tracking and verification of Swish Pro-Am sports merchandise. Swish Pro-Am athletes and teams will also connect with fans on the HUMBL social media platform through independently verified profiles, available to over 130+ countries. HUMBL will also activate sponsorship across the HUMBL platform through the HUMBL digital wallet, search engine, verified social media and authenticated, signed merchandise of the league for the 2023 Pro-Am Summer season.

09:02 EDT Hyundai Motor America reports May retail sales of 70,001 units, up 18% y/y - Hyundai Motor America reported total May sales of 70,001 units, an 18% increase compared with May 2022. Hyundai set best-ever total sales in May for Elantra HEV (+152%), Elantra N (+70%), IONIQ 5 (+28%), Santa Fe HEV (+266%), Tucson PHEV (+206%), Tucson HEV (+95%) and Santa Cruz (+12%). Hyundai fleet sales were 5,931 and represented 8.5% of total volume for the month.

08:56 EDT RenovoRx initiates patient enrollment in TIGeR-PaC trial - RenovoRx announced that the University of Texas, or UT, Southwestern Medical Center is now enrolling pancreatic cancer patients in the open label, randomized Phase III TIGeR-PaC clinical trial. The study is investigating RenovoGem which utilizes RenovoRx's proprietary therapy platform, TAMP, to provide improved and targeted intra-arterial delivery of FDA-approved gemcitabine chemotherapy to treat Locally Advanced Pancreatic Cancer, or LAPC.

08:48 EDT Real Good Food appoints Hussman to board of directors - The Real Good Food Company (RGF) announced the appointment of respected food industry executive Timothy Hussman to the Board of Directors, effective May 30, 2023. Hussman will serve as a member of the Audit Committee, as well as the Nominating & Corporate Governance Committee. Hussman served for over 35 years in varying roles of increasing responsibility within the meat industry, including 19 years in the Sysco Corporation (SYY) family of brands.

08:47 EDT Aleafia Health announces extension of forbearance under loan agreement - Aleafia Health announces that the Company has entered into a forbearance agreement with NE SPC II LP extending the forbearance period under its loan agreement with NE SPC until June 5, 2023. The forbearance agreement comes in light of ongoing negotiations between the Company, NE SPC and a potential alternative lender regarding a potential refinancing of the indebtedness existing under the Company's loan agreement with NE SPC dated December 24, 2021 and as previously amended by agreements dated March 28, 2022, June 17, 2022, and May 15, 2023. As previously disclosed by the Company, NE SPC recently agreed to amend the terms of the Loan Agreement and to forbear from enforcing its rights under the Loan Agreement until the earlier of an event of default, or May 31, 2023.

08:46 EDT Adeia renews IP license agreement with Japan's Bandai Namco Filmworks - Adeia (ADEA) announced that Bandai Namco Filmworks (NCBDY), a global leader in the creation and distribution of VOD anime content, has renewed its licensing agreement for Adeia's media intellectual property portfolio. "This agreement supports Bandai Namco Filmworks' ability to serve its subscriber base with new anime titles and an immense library of anime content. Adeia's IP underpins Bandai Namco Filmworks' efforts to deliver tailored user experiences by providing advanced content search, personalized recommendations and analytical features to elevate customer engagement," said Dr. Mark Kokes, Adeia's chief licensing officer and general manager of media.

08:45 EDT Veru appoints Swenson, Schooley to Infectious Disease SAB - Veru announced the appointment of Erik Swenson, M.D. and Robert Schooley, M.D. to its Infectious Disease Scientific Advisory Board, SAB, to join David Ho, M.D., who is Chairman of the SAB. Erik Swenson, M.D. is a pulmonologist affiliated with Veterans Affairs Puget Sound Health Care System-Seattle. Robert Schooley, M.D., an infectious disease specialist, is affiliated with UC San Diego Health-La Jolla and Hillcrest, where he serves as a Professor in the Division of Infectious Diseases at UC San Diego School of Medicine. Drs. Swenson and Schooley join David D. Ho, M.D., Chairman of Veru's SAB. David D. Ho, M.D. is the Founding Scientific Director of the Aaron Diamond AIDS Research Center and the Clyde and Helen Wu Professor of Medicine at Columbia University Irving Medical Center.

08:43 EDT Tingo to probe finanical institution accused of falsely marketing fundraise - The company said, "Tingo Group has become aware of credible evidence that a New York based financial institution has been soliciting investors with an offer of the Company's securities with the pretence of a fund raise, which was in direct contravention of the Company's explicit wishes. For the avoidance of all doubt, the Company is not planning any placement, offering, or issuance of the Company's equity securities. The Company has expressly instructed the NY Financial Institution not to conduct any such solicitation and also demanded that it notify all the parties solicited to date and inform them that the Company is not planning any form of equity fundraising. As announced on May 30, 2023, the Company's export business, operated through wholly owned subsidiary Tingo DMCC, completed its first batch of export deals generating USD $348 million of sales, with a gross profit approaching USD $100 million. The announcement also stated that Tingo DMCC has USD $1 billion of additional export transactions as part of an anticipated multi-billion-dollar long-term pipeline of business that is currently being processed for delivery by the end of the third quarter of 2023. For the avoidance of doubt, these export transactions do not require the Company to raise any equity funding. Furthermore, the export business is expected to dollarize the entire amount of Tingo Group's net income on a monthly basis by the end of 2023. The recent high levels of volatility in the Company's stock price, together with the significant increase in instances of false and malicious allegations on certain bulletin boards, social media accounts and websites, are currently being investigated by Warshaw Burstein LLP and Christian Attar Law, as part of the wider market manipulation investigation that was announced by the Company on February 7, 2023. Legal Counsel are also now conducting a full investigation of any potential claims the Company may have against the NY Financial Institution and others in relation to the false marketing of an equity raise."

08:38 EDT Coherus plans to launch YUSIMRY with lowest list price of adalimumab in US - Coherus BioSciences announced that the company plans to launch YUSIMRY in July 2023 with a list price of $995 per carton, the lowest price announced to date of any adalimumab offering in the United States. With Humira currently priced at $6,922 per carton of two autoinjectors, the YUSIMRY price will represent about an 85% discount from the originator. "Our YUSIMRY list price is a clear response to the challenges and needs of patients faced with high-cost adalimumab treatments today," stated Denny Lanfear, Coherus CEO. "We believe there is a large, unmet need for improved access and affordability in the U.S. health care system that YUSIMRY can address with this pricing. Our excellence in manufacturing and supply chain management gives us the ability to deliver safe and effective biosimilar adalimumab at low cost with ensured, reliable supply."

08:38 EDT GreenPower Motor: Three BEAST EV school buses delivered to CBS last month - GreenPower Motor announced that three BEAST all-electric school buses were delivered to its exclusive dealer Creative Bus Sales last month. In addition, CBS has more than 40 Type D BEAST and Type A Nano BEAST school buses for which HVIP voucher funding is either approved or are in the approval process.

08:36 EDT Nexalin Technology, Wider Come Limited formalize JV agreement - Nexalin Technology announced it has formalized a joint venture arrangement with Wider Come Limited. The JV, to be conducted through a company newly-formed under the laws of Hong Kong, will be engaged in the clinical development, marketing, sale and distribution of Nexalin's second generation transcranial Alternating Current Stimulation devices in China and the greater Asia Pacific region. In addition, Wider is contractually obligated to fund, have conducted, and have published the results of four separate clinical trials evaluating the treatment of patients with insomnia, depression, and other indications, utilizing Nexalin's Gen-2 devices. Previously, Wider served as an authorized distributor of the Company's Gen-2 devices in Asia. Wider's role is expanded under the newly-formalized JV to include the funding of all operations of the JV for the next 12 months, after which Nexalin and Wider plan to jointly fund the JV's operating expenses in accordance with their pro rata ownership. Wider and Nexalin will own 52% and 48% of the JV, respectively.

08:35 EDT IO Biotech appoints Christine Richter as SVP, commerical and program lead - IO Biotech announced that Christine Richter joined the company as SVP, Commercial and Program Lead for IO102-IO103, the company's lead cancer vaccine candidate. Dr. Richter will report to IO Biotech's CEO, Mai-Britt Zocca, Ph.D., and will be a member of the company's executive team. Richter is a pharma/biotech executive with a proven track record at companies including Amgen, Takeda Oncology, and most recently LEO Pharma.

08:34 EDT MDU Resources completes spinoff of Knife River - MDU Resources Group (MDU) announced that it has successfully completed the spinoff of its construction materials subsidiary, Knife River (KNF). As a result of the spinoff, Knife River is now an independent, public company that will begin "regular way" trading this morning on the New York Stock Exchange under the ticker symbol "KNF." MDU Resources shares will continue trading on the NYSE under the symbol "MDU."

08:33 EDT Blue Star Foods signs $1M supply agreement with Bloomin' Brands - Blue Star Foods (BSFC) announces it has entered into a new $1M supply agreement with Bloomin' Brands (BLMN). The new contract started distribution in April and will run through the remainder of 2023. Blue Star started to deliver approximately 115,000 pounds of pasteurized crab meat to Bloomin' Brands for its Outback Steakhouse crab related menu such as Crab-Topped Barramundi. John Keeler, Chairman and CEO of Blue Star Foods, commented, "We are very excited to enter into this new relationship with Bloomin' Brands for its Outback Steakhouse locations. Our crab meat enabled them to launch new & existing menu items. We feel confident with our outstanding quality & service, that there is an opportunity to expand further with Bloomin' Brands and its other wonderful restaurant concepts and menus."

08:33 EDT LyondellBasell signs MOU for joint new electric furnace technology - LyondellBasell has signed a memorandum of understanding with Technip Energies and Chevron Phillips Chemical to potentially design, construct and operate a demonstration unit using Technip Energies' electric steam cracking furnace technology - eFurnace by T.EN -. A joint development agreement is expected to be signed later this year. This new eFurnace technology could enable the company to use renewable electricity as a heat source for the olefins cracking process in the future, reducing the greenhouse gas footprint of its olefins production process, and helping the company meet its climate targets. Construction of the demonstration unit will enable the company to test the technology and confirm continuous olefin production is possible using electricity as a heat source. The three parties plan to assemble a joint development team to support implementation of the project. LyondellBasell is committed to reaching net zero scope 1 and scope 2 greenhouse gas emissions by 2050 and has set ambitious interim targets to reduce scope 1 and 2 GHG emissions 42%, and scope 3 GHG emissions 30% by 2030, relative to a 2020 baseline.

08:32 EDT ProPhase Labs provides update regarding progress, development for LB-1 - ProPhase Labs provided an update regarding its progress and development strategy for Linebacker-1, LB-1, a small molecule, multi-kinase inhibitor that is being developed by the Company's wholly owned subsidiary, ProPhase BioPharma, as a potential unique therapy option for several poor prognosis cancers. AH549 lung cancer cells completely lost the ability to proliferate over a 2-week period of treatment, while the HT29 colon cancer cells also saw significant inhibitory results. In the AH549 model, the Linebacker monotherapy showed zero cell proliferation, while the combination therapy showed some proliferation, and the control group showed massive cell proliferation. Also observed were synergies between Linebacker and low doses of frontline chemotherapeutic agents such as Doxorubicin in the colon cancer model. The initial observation is that Linebacker may have enhanced utlity as a combination therapy in cancer types that respond well or moderately well to Doxorubicin and should also be considered as a potential monotherapy for myriad cancers that previously showed no response. "We are truly excited about these ongoing preliminary results," said Ted Karkus CEO of ProPhase Labs. "While the results are still early and only in-vivo, they were better than we had initially expected, especially looking at this as a very viable monotherapy. To date, we have achieved excellent pre-clinical results for Linebacker as a combination therapy... We are anxiously awaiting the results of the in-vivo mouse tumor model testing as that, we believe, combined with our upcoming toxicology studies, should set Linebacker on an accelerated path to clinic."

08:25 EDT American Resources enters bond purchase agreement with Hilltop Securities - American Resources entered into a bond purchase agreement with Hilltop Securities, Inc., for the sale of the West Virginia Economic Development Authority preliminarily approved issuance of, and a volume cap allocation for $45,000,000 of private activity, Solid Waste Disposal Facility Revenue Bonds, Series 2023, for the Company's Wyoming County Coal complex located near the town of Oceana, West Virginia. On May 31, 2023, WCC entered into a Bond Purchase Agreement to sell West Virginia Development Authority Solid Waste Disposal Facility Revenue Bonds, Series 2023, at the purchase price of $45,000,000 less an underwriting discount of $900,000. The bonds hold an interest rate of 9% and a maturity date of June 8, 2038. The Bond Purchase Agreement is due to close on June 8, 2023, subject to customary closing conditions and document delivery.

08:23 EDT Siyata Mobile receives $1.2M order for UV350 devices, video monitoring - Siyata Mobile announced that it received an order for its UV350 In-Vehicle Devices and 'Siyata Real Time View,' the Company's newest product, valued at over $1.2M. The order is expected to begin shipping and recurring revenue to commence in the second quarter this year.

08:22 EDT Macy's: QTD demand trends have accelerated from April - Macy's says that the high-end of Q2, FY guidance ranges assume heightened macro pressures experienced in mid March through April persist, while the low-end of both contemplates potential deterioration as the year progresses.

08:20 EDT Macy's 'bullish' about small format store opportunity long-term, says Spring

08:19 EDT Panbela Therapeutics announces poster presentation at IDS meeting - Panbela Therapeutics announces a poster presentation highlighting the results for CPP-1X in recent onset type 1 diabetes at the Immunology of Diabetes Society, IDS, meeting, which was held May 23-27, 2023. The work reflects the Company's ongoing collaboration with Indiana University School of Medicine. "Preclinical studies showed that beta cell-specific deletion of ornithine decarboxylase provided protection against toxin-induced diabetes which suggests a role for polyamine dysregulation in T1D." said Jennifer K. Simpson, PhD, MSN, CRNP, President & Chief Executive Officer of Panbela. "Furthermore, results from the multi-site randomized, placebo-controlled Phase I trial in patients with recent onset T1D showed that inhibition of ODC by CPP-1X may improve beta cell function."

08:16 EDT Worksport launches new soft folding tonneau cover, SC4 PRO - Worksport announces the official launch of its latest product, the SC4 PRO soft folding tonneau cover. This cutting-edge addition to Worksport's product portfolio marks a significant milestone in the Company's commitment to truck bed innovations and sustainable revenue growth. "We are thrilled to introduce the SC4 PRO soft folding tonneau cover to the market," said Steven Rossi, CEO of Worksport. "This launch demonstrates our ongoing commitment to delivering innovative solutions that address the evolving needs of truck owners. The SC4 PRO combines functionality, durability, and style, offering a superior user experience. Our distribution partnerships with major retailers will enable us to reach a wide customer base, expanding our market presence and driving sustainable revenue growth."

08:11 EDT Macy's bringing Nike back to Macy's nameplate this year, says CEO

08:10 EDT Cerence appoints Marcy Klevorn to its board of directors - Cerence (CRNC) announced that Marcy Klevorn has been appointed to serve as an independent, non-executive director, effective today. In her more than 35-year career at Ford (F), Klevorn held varying executive and leadership roles within the company's information technology organization, including global Chief Information Officer (CIO) and, previously, CIO of Ford Motor Company in Europe.

08:09 EDT NRG Energy says Bruce Chung to succeed Alberto Fornaro as CFO - NRG Energy announced that Bruce Chung will succeed Alberto Fornaro as Chief Financial Officer, effective June 1 Fornaro will be pursuing other interests but will remain with NRG as a strategic advisor during this transition period until September 1. "I want to thank Alberto for his leadership during the last two years and for further strengthening our finance and risk infrastructure while developing a talented team aligned with our overall strategic goals. On behalf of the Board and the entire NRG team, we want to thank Alberto for his many contributions and wish him well in his new endeavors," said Mauricio Gutierrez, President and CEO. "As we look into the next phase of our evolution, I am confident that Bruce is the right person to lead the finance organization going forward, given his deep industry experience and knowledge of our company."

08:06 EDT MEI Pharma board rejects unsolicited proposal from Anson-Cable Car - MEI Pharma announced that its Board of Directors reviewed and rejected the unsolicited and non-binding proposal received on May 23 from a group represented by Anson Advisors Inc. and Cable Car Capital to acquire all outstanding shares of MEI for not less than $8.00 in cash per share, plus a contingent value right representing the right to receive 80% of the net proceeds payable from any license or disposition of the Company's clinical assets. The Board, in consultation with the Company's financial and legal advisors, concluded that the unsolicited proposal significantly undervalues the Company, is not superior to the proposed transaction with Infinity Pharmaceuticals, and does not provide a basis for discussions regarding an alternative transaction.The recommendation by the MEI Board to proceed with the pending Infinity transaction remains unchanged. MEI shareholders are advised that no action is necessary at this time. Stifel is serving as financial advisor to MEI Pharma and Morgan Lewis is serving as legal counsel.

08:06 EDT Horizon Therapeutics publishes new biomarker data from N-MOmentum trial - Horizon Therapeutics announced the publication of new data from the Phase 3 N-MOmentum pivotal trial of Uplizna, which offer insights on serum biomarkers that signal acute attacks and disability worsening associated with NMOSD and illustrate the role of Uplizna in reducing these biomarker levels, potentially reducing the frequency and severity of these attacks. The results of this analysis are published in The Journal of Neurology, Neurosurgery and Psychiatry. NMOSD is most notably associated with acute attacks, which can cause irreversible damage to the optic nerve, spinal cord, brain and brain stem. Disease management goals are focused on prevention of attacks, as well as understanding and tracking biomarkers that could signal these attacks. The N-MOmentum pivotal trial of Uplizna, which demonstrated the effects of the treatment in reducing the attacks associated with NMOSD, included analyses of biomarkers linked to disease activity and neuronal injury: serum neurofilament light chain, serum glial fibrillary acidic protein, ubiquitin C-terminal hydrolase L1 and tau. The trial identified important biomarker trends associated with NMOSD attacks. Throughout the 28-week randomized controlled trial period, or RCP, and the two-year open-label follow-up period, the concentration of all four biomarkers increased during NMOSD attacks, and in the days leading up to attacks. Of the four biomarkers evaluated in the trial, sNfL measured at the time of attack was the strongest predictor of worsening disability during and after attacks. The strong link suggests that higher sNfL levels may be associated with more severe attacks and increased risk of residual disability. However, only levels of sGFAP were determined to be predictive of future attacks, building upon prior research studying that biomarker in particular. Importantly, biomarker changes among Uplizna-treated participants in the trial reinforced the effects of this medicine. Compared with placebo, Uplizna was shown to hinder biomarker elevation during attacks while reducing biomarker levels over time in the absence of attacks. Participants treated with Uplizna had significantly lower levels of sNfL at the end of the RCP compared to placebo, and numerically lower levels of the other three biomarkers. Among patients who did experience attacks, those treated with Uplizna had lower biomarker levels during attacks versus those who received placebo, reflecting potentially less severe events, and sGFAP levels were significantly lower with UPLIZNA among those who did not experience attacks versus placebo.

08:04 EDT Treasure Global's ZCITY announces collaboration with ZUS Coffee - Treasure Global announced that its proprietary lifestyle app, ZCITY, will partner with tech-enabled Malaysian coffee chain, ZUS Coffee, to provide exclusive incentives for new ZCITY users on coffee purchases from ZUS. The collaboration allows ZCITY and ZUS Coffee to tap into each other's significant user bases, attracting new customers to ZCITY, growing brand reach and recognition, expanding market reach, and offering rewards for consumers. ZCITY currently has over 2.4 million registered users, while ZUS Coffee has 230 coffee outlets in Malaysia. In addition, ZUS Coffee plans to open over 100 new outlets throughout the country in 2023, providing a significant future partnership opportunity for ZCITY. "By leveraging technology and fostering strategic collaborations, ZCITY continues to revolutionize how individuals approach their everyday expenditures, providing rewards that will help our users gain savings on everyday items, such as coffee. We are excited to partner with ZUS Coffee to provide an affordable solution that allows our users to enjoy their favorite cup of coffee without straining their wallets. The collaboration will enable ZCITY and ZUS Coffee to leverage our combined significant customer bases to grow our reach, increase user acquisition and enhance brand recognition, in line with our regional expansion plans," said Sam Teo, Founder and Chief Executive Officer of ZCITY.

08:04 EDT PriceSmart opens third warehouse club in El Salvador - PriceSmart announced that on May 4 the company opened its newest warehouse club in San Miguel, El Salvador, bringing the total number of warehouse clubs in operation by the company to 51. The San Miguel club is the third club in El Salvador and was constructed on a five-acre property in the Hacienda San Andres area, approximately 100 miles east of the capital city San Salvador.

08:04 EDT Macy's: Demand trends worsened in mid-March, decelerated in April - The U.S. consumer pulled back more than anticipated, the company said. Comments taken from Q1 earnings conference call.

08:02 EDT PaxMedica completes HAT-301 registrational trial for PAX-101 - PaxMedica announced that the eligibility review and final enrollment for the company's Real World Evidence study has been completed. Patient eligibility was assessed for inclusion by an Independent Study Adjudication Committee which included a total of three subject matter expert medical reviewers. The comparative arms for this pivotal Phase 3 Real World Evidence study included: A total of 145 patients treated with suramin in Uganda and Malawi between 2000 - 2022, and A total of 204 natural history cases from patients in Uganda and Malawi between 1900-1910, prior to the availability of suramin. Howard Weisman, Chief Executive Officer of PaxMedica, commented, "Database lock for the HAT-301 study is a significant threshold event for PAX-101. With this achievement, PaxMedica has completed a critical step in filing for potential U.S. market approval for this important, life-saving treatment. The opportunity to raise significant non-dilutive funding, as a result of our potential successful participation in the Neglected Rare Tropical Disease Program through receipt of a PRV, may enable future large-scale trials of PAX-101 in Autism, and other important conditions, in the very near future. This remains central to our strategy to build and support sustainable long term shareholder value."

08:02 EDT DZS to restate Q1 financial statements - DZS announced that it will restate its previously issued financial statements for the first quarter of 2023, which ended March 31, 2023. The restatement relates to timing of revenue recognition with respect to two customer projects. The value of the revenue to be restated is approximately $15 million, of which the company anticipates the majority will be recognized during the second and third quarters of 2023. The associated customer relationships are in good standing, and the customers have begun paying the amounts due to the Company.

07:59 EDT Getty Images, iStock launch Creative Accelerator Program - Getty Images and iStock announced the launch of their Creative Accelerator Program, a new initiative aimed at recruiting and onboarding early to mid-career creators from underrepresented backgrounds and demographics to shape the next generation of talent.

07:40 EDT Nextech3D.ai demonstrates fixed point diffusion of 2D to 3D model conversion - Nextech3D.AI executed an end-to-end demonstration in the real-world of its "FIXED POINT DIFFUSION FOR ROBUST 2D TO 3D CONVERSION" technology to be used for e-commerce. Nextech3D.ai uses fixed-point diffusion for learning to construct 3D models from 2D reference photos as was described in a recently filed provisional patent.

07:38 EDT Anavex announces issuance of new U.S. patent for ANAVEX 2-73 - Anavex Life Sciences announced it was awarded new U.S. Patent No. 11,661,405 entitled "CRYSTAL FORMS OF TETRAHYDRO-N,N-DIMETHYL-2,2-DIPHENYL-3-FURANMETHANAMINE HYDROCHLORIDE, PROCESSES OF MAKING SUCH FORMS, AND THEIR PHARMACEUTICAL COMPOSITIONS" from the United States Patent and Trademark Office, expanding Anavex's patent coverage of certain crystal forms of ANAVEX2-73 compositions, processes of preparation, and uses thereof. Anavex's newest patent will be expected to remain in force at least until October 2036, not including any patent term extensions. The new patent will expand the coverage of certain ANAVEX2-73 crystals covered by U.S. Patent No. 10,413,519, to methods of their making. "This new patent relating to ANAVEX2-73 is exceptionally important for ANAVEX, because all clinical trials with ANAVEX2-73, including Alzheimer's disease Phase 2b/3 ANAVEX2-73-AD-004 study are using the patent protected crystal forms as the active pharmaceutical ingredient," said Christopher Missling, PhD, President and Chief Executive Officer of Anavex. "We are extremely pleased with the continued development of the patent portfolio for ANAVEX2-73 which demonstrates our continued commitment to protecting all aspects of the Anavex product portfolio."

07:37 EDT Aehr Test Systems announces new customer, initial order for FOX-XP - Aehr Test Systems announced a new silicon carbide semiconductor customer and initial order for a FOX-XP multi-wafer test and burn-in system, multiple WaferPak Contactors, a WaferPak Aligner, and a high-volume production support kit to be used for volume production of silicon carbide MOSFETs for electric vehicles, trucks, and train traction inverter modules. The turnkey system including the FOX-XP, WaferPak Contactors and WaferPak Aligner is expected to ship within the next two quarters. Gayn Erickson, President and CEO of Aehr Test Systems, commented, "We are very excited that after conducting an evaluation of technical and commercial requirements, this new customer has decided to move very quickly to purchasing our production FOX-XP solution to accelerate their time to market. This evaluation included cost of ownership, customer device module yield improvement, system capacity and throughput, and device test, burn-in, and stabilization coverage. They see the enormous opportunity in the silicon carbide market, particularly for the traction inverters used in electric vehicles including trucks, and in electric commuter trains where they believe they can provide a superior product of long-term reliability and useful life. Importantly, these new applications represent new market drivers for our system. This customer is forecasting to grow their silicon carbide business significantly, which we believe will drive incremental capacity for our FOX systems as well as WaferPak Contactor purchases for capacity and new designs."

07:36 EDT AvidXchange announces Lien Waiver Management for TimberScan - AvidXchange Holdings announced Lien Waiver Management for TimberScan, a premium feature embedded in AvidXchange's full purchase-to-pay solution with a seamless Sage 300 CRE integration. With Lien Waiver Management, construction industry professionals are offered an improved payment process by associating the release of funds with the receipt and inspection of the lien waiver, ultimately reducing construction project delays. Lien Waiver Management supports all four lien waiver types including, Partial Conditional, Partial Unconditional, Final Conditional and Final Unconditional within the TimberScan platform.

07:35 EDT MPM BioImpact affiliates to acquire Reunion Neuroscience for $1.12 per share - Reunion Neuroscience has entered into a definitive arrangement agreement dated May 31, 2023 with MPM BioImpact, whereby affiliates of MPM would acquire Reunion in an all-cash transaction valued at approximately $13.1 million by way of a statutory plan of arrangement under the Canada Business Corporations Act. Pursuant to the terms and conditions of the Arrangement Agreement, all holders of outstanding common shares of Reunion will be entitled to receive $1.12 in cash for each Share held immediately prior to the effective time of the Arrangement. Based on the Bank of Canada daily exchange rate as of the close of business on May 31, 2023, this would be approximately $1.52 per Share in Canadian dollars, representing a premium of approximately 43.1% over the trailing 30-trading-day volume weighted average price. Reunion's board of directors, after consultation with its financial and legal advisors and acting on the unanimous recommendation of a special committee of independent directors of Reunion, has determined that the Arrangement is in the best interests of the Company and is fair to Shareholders. The Board unanimously recommends that Shareholders vote IN FAVOUR of the Arrangement at a special meeting of Shareholders expected to be held on or around July 12, 2023. The Company has fixed a record date of June 12, 2023 for purposes of determining Shareholders entitled to receive notice of, to attend and to vote at the Meeting. Completion of the Arrangement will, among other things, require the approval by at least two-thirds of the votes cast by the Shareholders at the Meeting. Certain Shareholders, and all of the Company's officers and directors, representing in aggregate approximately 34% of the issued and outstanding Shares, have entered into voting and support agreements with MPM in support of the Arrangement. Completion of the Arrangement remains subject to the satisfaction of a number of conditions precedent, including, but not limited to the following material conditions: approval of the Shareholders at the Meeting; obtaining all applicable regulatory approvals, including approval of the Ontario Superior Court of Justice of the Arrangement; the net cash held by the Company being equal to or greater than $8,000,000 as of the close of business on the third business day immediately prior to closing of the Arrangement; and the performance or completion in all material respects with all obligations required to be performed by the Company and MPM under the Arrangement Agreement. Subject to the satisfaction or waiver of the conditions precedent for completion of the Arrangement, the Arrangement is expected to close in the calendar third quarter of 2023. Upon completion of the transaction, Reunion will no longer be traded or listed on any public securities exchange and will be wholly-owned by affiliates of MPM.

07:31 EDT Lyra Therapeutics sees cash runway into 1Q25 - Lyra Therapeutics announced the closing of its previously announced private placement of common stock, pre-funded warrants to purchase common stock and purchase warrants to purchase common stock, resulting in gross proceeds of approximately $50.0 million. The private placement includes participation from new and existing investors, including Perceptive Advisors, Venrock Healthcare Capital Partners, Armistice Capital, Surveyor Capital, North Bridge Venture Partners, Nantahala Capital, Samsara BioCapital, and Woodline Partners LP. Lyra ended the first quarter of 2023 with cash, cash equivalents and short-term investments of $82.7 million. Combined with the net proceeds from the private placement, the Company anticipates that it will have sufficient cash, cash equivalents and short-term investments to fund current planned operations into the first quarter of 2025.

07:24 EDT NioCorp completes geotechnical drilling campaign at Elk Creek - NioCorp Developments announced the completion of a geotechnical drilling campaign at the Elk Creek Critical Minerals Project in southeast Nebraska, which was done in advance of the proposed site preparation, grading, heavy construction, and eventual foundation pours for the Elk Creek Project that are expected to commence once sufficient financing is obtained. The campaign involved drilling 16 boreholes and 20 test pits across the one square mile Elk Creek Project site, analyzing soil samples, and generating data for engineering design firms that are continuing to finalize plans for the potential construction of the facility. The drilling explored the "glacial till" geological layer, which is comprised of the first 30 meters or so of soil, clay, and sand that covers much of southeast Nebraska. This layer of sediment was deposited by repeated glaciation that occurred in the Pleistocene epoch that ended approximately 11,000 year ago.

07:21 EDT Bio-Techne prevails on claim by Miltenyi Biotec - Bio-Techne announced that it prevailed on a claim that Miltenyi Biotec B.V. & Co. KG commercialized antibodies it developed based on information obtained by reverse engineering Bio-Techne's proprietary R&D Systems branded TIGIT and CCR-7 antibodies. Specifically, the Court held "it has been proven that TIGIT and CCR-7 antibodies are the result of reverse engineering of antibodies." In addition to finding that Miltenyi has been marketing and selling these reverse engineered antibodies, the court determined that Bio-Techne is entitled to monetary damages and additional detailed information regarding the scope of Miltenyi's unlawful reverse engineering activities. Bio-Techne took legal action against Miltenyi at the Regional Court of Cologne, Germany after discovering the variable regions of Miltenyi's TIGIT and CCR-7 antibodies, including the complementarity determining regions which confer antibody specificity, were almost 100 % identical to the R&D Systems antibodies. This discovery took place following suspicious purchasing activity from Miltenyi for these specific R&D Systems branded antibodies spanning more than a decade. The Court agreed with its appointed expert's determination that "the probability of obtaining two antibodies, independently of each other, which are identical in the VH and VL domains by independently immunizing two different animals at different times in different locations is vanishingly small."

07:19 EDT Solaris Resources reports assay results from Warintza Project - Solaris Resources is pleased to announce assay results confirming the discovery of a second porphyry center featuring the highest grades to date at Warintza East, with strong mineralization starting from bedrock surface extending to the end of the hole. The new zone is open to the east, west, south and at depth, with follow-up drilling already underway at this important new discovery at the Warintza Project in southeastern Ecuador. Highlights: Warintza East was discovered in July 2021, with eight drill holes included in the Warintza Central Mineral Resource Estimate in April 2022. Subsequent drilling has significantly expanded the dimensions of the deposit, with ongoing drilling targeting further mineral resource growth; The latest drilling made an important discovery of a second, more intensely-mineralized porphyry center located outside the MRE, approximately 350m south of the original discovery, with assays now confirming the highest grades encountered at Warintza East to date; SLSE-28 was collared to the south of the Warintza East drill grid and drilled vertically to the limit of the KD-200 rig, returning 301m of 0.65% CuEq from bedrock surface at 8m depth to the end of the hole, with the final 31m averaging 0.76% CuEq; Two new platforms were constructed to the east and west, also outside the MRE, with follow-up drill hole SLSE-29 testing the southeast extension up to 200m to the east now completed and SLSE-30 in progress testing the potential to the west; SLSE-29 and SLSE-30 were both drilled with KD-200 rigs to allow for the rapid expansion of this emerging zone of near surface, high grade mineralization, with follow-up deeper drilling planned with larger capacity KD-1400 rigs; The new zone is wide open and additional follow-up drilling is planned to test the potential for lateral expansion, focusing on vectors to the south and southeast where new step-out platforms are under construction. Jorge Fierro, Vice President, Exploration, commented, "The discovery of a second, significantly higher grade porphyry center at Warintza East is a welcome surprise in our ongoing mineral resource growth drilling program. This new zone offers the potential to rapidly add near surface, high grade mineralization to the deposit that could contribute to future starter pit growth. Moreover, the zone is wide open with step-out and extension drilling coming soon."

07:18 EDT GDS Holdings repurchases $299.9M of Convertible Senior Notes - GDS Holdings repurchased approximately $299,910,000 aggregate principal amount of its 2.00% Convertible Senior Notes due 2025. Pursuant to the Indenture dated as of June 5, 2018 relating to the Notes by and between the Company and The Bank of New York Mellon, as trustee, each holder had the right, at the option of such holder, to require the Company to repurchase all of such holder's Notes or any portion thereof that is an integral multiple of $1,000 principal amount for cash on June 1, 2023. The repurchases were consummated through holders' exercise of the Repurchase Right. The repurchased Notes will be canceled accordingly. Notes in the aggregate principal amount of S$80,000 remain outstanding after such repurchases.

07:16 EDT Ionis Pharmaceuticals reports 'positive' clinical progress with donidalorsen - Ionis Pharmaceuticals announced positive clinical progress with donidalorsen, its late-stage investigational prophylactic therapy for hereditary angioedema. Topline two-year open-label extension results continue to demonstrate consistent efficacy and safety, with an overall sustained mean reduction in HAE attack rates of 96% from baseline through two years across dosing groups. The company also announced that it has completed enrollment in the Phase 3 OASIS-HAE study, which is evaluating the safety and efficacy of donidalorsen in preventing angioedema attacks. Topline data from the study are expected in the first half of 2024. HAE is a rare and potentially fatal genetic disease characterized by severe and potentially fatal swelling of the arms, legs, face and throat.

07:14 EDT Lantronix to display OOB software, hardware solutions at Cisco Live - Lantronix (LTRX) announced that it will display its Out-of-Band, OOB, management solutions at booth Number 9203 at Cisco (CSCO) Live, June 4-8, 2023, in Las Vegas. For the first time in North America, Lantronix will showcase its expanded line of Out-of-Band solutions. "While enterprise networks vary widely in form and function, good management is always essential. Our advanced out-of-band management solutions ensure secure access to remote gear during an outage while automating many daily tasks that can unnecessarily consume much of a network admin's day," said Jacques Issa, VP of Marketing at Lantronix Inc. "Cisco Live is the perfect venue in which to showcase our software, hardware and services that support this vital industry."

07:12 EDT Axsome Therapeutics to present new Sunosi data at SLEEP 2023 - Axsome Therapeutics announced presentations on Sunosi at SLEEP 2023, the annual meeting of the American Academy of Sleep Medicine and the Sleep Research Society, being held in Indianapolis, Ind., from June 3-7, 2023. The presentations include new data from the SHARP study in patients with excessive daytime sleepiness associated with obstructive sleep apnea, demonstrating sustained improvement with Sunosi on measures of cognition across 8-hours with once daily dosing. Additional new data and analyses include real-world data from OSA patients taking Sunosi as part of the SURWEY study in Germany, healthcare resource use in OSA patients with residual EDS, and effect sizes and numbers needed to treat analyses. "Cognitive impairment is a substantial burden to many patients with EDS and OSA. The results of the SHARP study are particularly exciting because they demonstrate a robust improvement in cognitive function that was sustained throughout the day," said Hans Van Dongen, PhD, Professor at Washington State University and first author of the SHARP study abstract. "Not only was there an objective change in cognitive performance, but patients also reported a measurable improvement in their symptoms, suggesting solriamfetol can be an effective option for the treatment of patients with EDS due to OSA."

07:12 EDT Clearside Biomedical opens enrollment in ODYSSEY Phase 2b trial of CLS-AX - Clearside Biomedical announced that enrollment has opened in ODYSSEY, its Phase 2b clinical trial of CLS-AX using suprachoroidal delivery in neovascular age-related macular degeneration. "With the ODYSSEY clinical trial now open for enrollment, we are excited to continue exploring the potential of CLS-AX to provide an effective and less burdensome treatment option in the multi-billion-dollar wet AMD market," said George Lasezkay, Pharm.D., J.D., Clearside's President and Chief Executive Officer. "CLS-AX will be delivered via our patented SCS Microinjector giving us unprecedented access to the back of the eye to directly target the site of the disease behind the visual field. We believe that our potent and well-tolerated tyrosine kinase inhibitor combined with targeted suprachoroidal delivery has the potential to produce promising results in our Phase 2 clinical trial. Our primary goals for ODYSSEY are to maintain visual acuity and demonstrate improved duration with reduced treatment burden for the CLS-AX arm. We believe that the number of participants, duration, and outcome measures of the study will provide the necessary clinical data to design a CLS-AX Phase 3 program. We are targeting a total of 30 U.S. based clinical trial sites for ODYSSEY and expect to report topline data from the trial in the third quarter of next year," concluded Dr. Lasezkay.

07:09 EDT NRG Energy upsizes share repurchase agreement to $1B - The NRG board of directors authorized $650M in share repurchases to be initiated following the closing of the STP sale. This authorization, when combined with the approximately $350M remaining under the existing share repurchase program, brings the total amount of share repurchases to be completed to $1B. NRG reiterates its expectation to achieve its investment grade 2.50x to 2.75x corporate net debt to adjusted EBITDA credit metrics by late 2025 or 2026.

07:08 EDT Scorpio Tankers announces repurchase of common shares - Scorpio Tankers announced that it has recently purchased 851,978 of its common shares in the open market at an average price of $46.74 per share as part of the company's securities repurchase program. The company currently has 55,331,704 common shares outstanding. On May 31, 2023, the company's Board of Directors replenished the 2023 Securities Repurchase Program to purchase up to an aggregate of $250M of the company's securities which, in addition to its common shares also consist of its Senior Unsecured Notes Due 2025. This program resets the program that was previously replenished on May 1, 2023. There is $250M available under the 2023 Securities Repurchase Program as of June 1, 2023.

07:08 EDT Xtract One to deploy SmartGateway solution at City of Phoenix court building - Xtract One announced its SmartGateway patron screening solution will be deployed by the City of Phoenix to increase security and ensure public safety at the City's Court Building, which houses the courtrooms for the Phoenix Municipal Court. Xtract One's SmartGateway solution uses AI-powered sensors to unobtrusively scan patrons for guns, knives, and other prohibited items as they enter the facility. SmartGateway replaces traditional metal detectors and delivers fast, reliable, and accurate patron screening without invading the sense of privacy and comfort of patrons.

07:06 EDT Wearable Devices starts manufacturing Mudra Band for Apple Watch - Wearable Devices (WLDS) announces that it has commenced commercial manufacturing of its anticipated Mudra Band for Apple Watch (AAPL). "We are focused on manufacturing an excellent product that will transform the way people interact with their electronic devices. A key focus of our development process has been to optimize design for manufacturability so we can efficiently complete the manufacturing process and deliver the preorders to our customers," stated Guy Wagner, co-founder and Chief Scientist Officer of Wearable Devices. "Our team is dedicated to ensuring a seamless production process, and we look forward to introducing the Mudra Band to our valued customers. This is just the beginning of our journey, our preorders further validate the market's anticipation for this revolutionary touchless product."

07:05 EDT Verano Holdings announce opening of MUV Miami Kendall - Verano Holdings announced the opening of MundefinedV Miami Kendall on Friday, June 2, the Company's 68th Florida dispensary and 129th retail outlet nationwide. MundefinedV Miami Kendall - Verano's first dispensary in Miami-Dade County - is located at 9711 SW 77th Avenue, and will be open Monday through Saturday from 9 a.m. to 7 p.m. and Sunday from 11 a.m. to 5 p.m., local time.

07:05 EDT Bausch + Lomb chief quality officer Louis Yu to retire - Bausch + Lomb announced a reshaping of its executive leadership team, including the retirement of Louis Yu, chief quality officer. Yu has notified Bausch + Lomb of his intent to retire later this summer, and the company will commence an internal and external search for his replacement.

07:04 EDT International Game signs three-year contract extension with AB Svenska Spel - International Game Technology announced it signed a three-year contract extension with AB Svenska Spel to continue providing leading-edge video lottery technology and services including the INTELLIGEN central system, more than 4,000 Quasar Video Lottery Terminals, high-performing games, award-winning IGTPay cashless technology and more. This contract extension will run through January 2027.

07:02 EDT Dollar General lowers FY23 EPS growth view to (8%)-0% from 4%-6% - Consensus for FY24 EPS is $11.14. Lowers FY23 revenue growth view to 3.5%-5.0% from 5.5%-6%, consensus $40B. Lowers Same-store sales growth view to 1.0%-2.0% from its previous expectation of 3.0%-3.5%.

06:59 EDT Macy's: $200M of incremental cost savings expected to be realized in FY23

06:54 EDT The Buckle reports May SSS down 6.4% - The Buckle announced that comparable store net sales, for stores open at least one year, for the 4-week period ended May 27, 2023 decreased 6.4 percent from comparable store net sales for the 4-week period ended May 28, 2022. Net sales for the 4-week fiscal month ended May 27, 2023 decreased 5.3 percent to $89.3 million from net sales of $94.3 million for the prior year 4-week fiscal month ended May 28, 2022.

06:53 EDT Constellation Energy to acquire ownership stake in Texas nuclear plant - Constellation (CEG) announced it is acquiring NRG Energy's (NRG) 44% ownership stake in the South Texas Project Electric Generating Station, a 2,645-megawatt, dual-unit nuclear plant located about 90 miles southwest of Houston. The transaction is valued at $1.75B, with an effective purchase price of $1.4B after taking into consideration the present value of tax benefits to Constellation. The transaction will be financed with a combination of cash and debt.

06:48 EDT Telus International names Jose-Luis Garcia as COO - Telus International announced the appointment of Jose-Luis Garcia as the company's COO, effective June 1.

06:37 EDT AstraZeneca discontinues brazikumab IBD development program - AstraZeneca announced the discontinuation of the brazikumab inflammatory bowel disease, or IBD, development program, an anti-IL-23 monoclonal antibody, being investigated for the treatment of Crohn's disease and ulcerative colitis. "The IBD development programme for brazikumab included the Phase IIb/III INTREPID trial in CD and the Phase II EXPEDITION trial in UC, and their respective open-label extension trials. The decision to discontinue brazikumab's IBD development follows a recent review of brazikumab's development timeline and the context of a competitive landscape that has continued to evolve. The timeline was impacted by delays that could not be mitigated following global events. No safety concerns were identified for patients in these trials. Under an agreement from 2020, AbbVie contributed to ongoing funding of the development programme, but this funding will now cease," the company stated.

06:34 EDT International Game announces three-year contract extension with AB Svenska Spel - International Game announced it signed a three-year contract extension with AB Svenska Spel to continue providing leading-edge video lottery technology and services including the Intelligent central system, more than 4,000 Quasar Video Lottery Terminals, games, IGTPaycashless technology and more. This contract extension will run through January 2027.

06:15 EDT Ford Next partners with Uber on new lease option for drivers going electric - Ford Next (F) is collaborating with Uber (UBER) to deliver a new lease option for rideshare drivers going electric. Called Ford Drive, the pilot program offers flexible access to Ford Mustang Mach-E models and has launched in San Diego, San Francisco, and Los Angeles. Ford Drive's Los Angeles vehicle deliveries began today. A flexible lease allows rideshare drivers to select their Mustang Mach-E for between one- and four-month increments, depending on the location. The vehicle is delivered to the driver within two weeks, and they use the Ford Drive app to manage payments and service. In each city, the Ford Drive team works with local dealers to purchase a fleet of Mustang Mach-Es. Service and maintenance of those vehicles are conducted through dealers as well. Ford Next and Uber initially launched the flexible lease pilot in 2022, allowing San Diego drivers on the Uber platform to lease more than 150 Mustang Mach-Es. Now, drivers in three California cities are able to test drive this new leasing approach. California is Uber's leading North American market for EV uptake, with close to 10% of all on-trip miles completed in fully electric vehicles as of late 2022.

06:01 EDT Amarin: EddingPharm receives regulatory approval for VASCEPA - Amarin announced that its commercial partner in China, EddingPharm, has received regulatory approval for VASCEPA from China's National Medical Products Administration. NMPA granted approval for VASCEPA as an adjunct to diet to reduce triglyceride levels in adult patients with severe hypertriglyceridemia. Following regulatory approval, EDDING is now focusing on National Reimbursement Drug Listing and preparing for commercial launch in China, expected by year-end, as well as on advancing regulatory submission and review for an additional indication in cardiovascular risk reduction.

05:59 EDT Walmart raising wages for 7,700 pharmacists, opticians - Walmart announced Wednesday that it has raised pay for approximately 3,700 pharmacists "as we continue our work to offer attractive pay in every market where we operate. Our average salary for pharmacists is now more than $140,000, not including bonuses and incentives. Those investments build on the raises for 36,000 pharmacy technicians that took place last year. Being an employer of choice also means better work life balance and listening to our customers and associates, which we did earlier this year when we adjusted our hours at pharmacies and vision centers across the country. We're also excited to share we'll be raising pay for more than 4,000 opticians. After these investments, we expect the average wage for opticians to be more than $22.50 an hour. It's another step in our strategy to offer good jobs that lead to great careers... This is all part of our ongoing effort to recognize the great work of our Health & Wellness associates while investing for the future." Reference Link

05:32 EDT XPeng delivers 7,506 Smart EVs in May - XPeng announced its vehicle delivery results for May. In May, XPeng delivered 7,506 Smart EVs. The delivery volume of the P7i has experienced a substantial increase compared to the previous month. The company will further accelerate deliveries of the P7i in June, with the goal of rapidly bringing customers this popular new model that features outstanding style and design aesthetics and distinguishing smart features.

05:11 EDT CNH Industrial appoints Friedrich Eichler as CTO - CNH Industrial announced the appointment of Friedrich Eichler as CTO. He will preside over the company's R&D community with direct responsibility for technology, innovation, quality, Design and their related divisions Friedrich will provide functional governance for the agriculture and construction segments' product development - coordinating closely with segment presidents Derek Neilson and Stefano Pampalone.